SOUTH SAN FRANCISCO, Calif., March 1 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2006.
For the fourth quarter of 2006, the company reported a net loss of $30.3 million, or $0.54 per fully diluted share, compared with net income of $19.1 million, or $0.33 per fully diluted share, for the same period in 2005. The increase in net loss in the current quarter is attributed primarily to the absence of gains from sales of marketable securities compared to the fourth quarter of 2005, at which time the company had a gain of $48.8 million from the sale of 3.0 million shares of common stock of Abgenix, its former subsidiary.
For the year ended December 31, 2006, the company had a net loss of $82.9 million, or $1.67 per share, compared with $64.9 million, or $1.43 per share in 2005. The increase in net loss in 2006 is primarily due to an income tax provision recorded in 2006 relating to the realized gain from the sale of 3.0 million shares of Abgenix common stock in 2006.
The company's research and development costs were $24.6 million and $96.3 million in the fourth quarter and year ended December 31, 2006, respectively, compared with $21.0 million and $92.4 million for the comparable periods of 2005. R&D expenses for the full year of 2006 are higher primarily due to the expansion of Phase 3 clinical trials of the company's lead product development program, GVAX immunotherapy for prostate cancer, to Europe and included $4.6 million in non-cash stock-based compensation expense recorded under Statement of Financial Accounting Standards No. 123 revised 2004 (FAS 123R). General and administrative expenses were $4.4 million and $18.1 million in the fourth quarter and year-ended December 31, 2006, respectively, compared with $5.0 million and $16.3 million for the comparable periods of 2005. G&A expenses for the full year of 2006 are higher primarily due to recording $1.3 million in 2006 of non-cash stock-based compensation expenses related to adoption of FAS 123R.
Cell Genesys ended 2006 with approximately $154.1 million in cash, cash equivalents and short-term investments.
"We are pleased with our product development progress during 2006, particularly that of our lead program, GVAX immunotherapy for prostate cancer, which is now being evaluated in two Phase 3 clinical trials in the U.S., Canada and Europe. During 2006, we reported encouraging additional clinical data for this product, both in Phase 2 single agent and Phase 1 combination immunotherapy trials," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "We are pleased to continue to have the financial resources we need to move our clinical programs forward in pursuit of our goal of bringing novel biological therapies to patients with cancer."
Recent Highlights: -- Reported at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium in January 2007, follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer in 60 patients with operable pancreatic cancer who received the immunotherapy after surgical resection of their tumor and adjuvant radiation and chemotherapy. The updated results showed a median survival of 26.8 months. This compares favorably with published, historical data from multiple single-arm and randomized studies in patients undergoing pancreatic cancer surgery and adjuvant therapy for whom the median survival has been reported to be in the range of 17 to 22 months, including the most recently reported results for gemcitabine chemotherapy. -- Entered into a new Committed Equity Financing Facility, with Kingsbridge Capital Limited in February 2007, pursuant to which Kingsbridge committed to purchase, subject to certain conditions, up to $75 million of our common stock. The company had previously raised $35.0 million in a similar transaction with Kingsbridge. -- Reported at the ASCO Prostate Cancer Symposium last week, encouraging follow-up data on the first twelve patients with advanced prostate cancer treated on a Phase 1 clinical trial of Cell Genesys' GVAX immunotherapy for prostate cancer, administered in combination with Medarex's fully human anti-CTLA-4 antibody, ipilimumab (MDX-010). The twelve patients who have completed treatment to date include six patients who received the combination therapy at doses currently being evaluated in both GVAX and ipilimumab Phase 3 clinical trials. Antitumor activity has been observed in five of these six patients including prostate-specific antigen (PSA) declines of greater than 50% that were maintained in four of these patients for at least six months with the longest response ongoing at more than 12 months. Moreover, clinical evidence of antitumor activity has been observed in three of these five PSA responders, including improvement of multiple lesions on bone scan, resolution of abdominal lymph node disease by CT scan, and improvement in pain due to bone metastases, respectively. Two additional patients have had stable disease on bone scan for at least three months.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapy for pancreatic cancer and leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.
Cell Genesys will host its quarterly and year-end conference call to discuss events that occurred during the fourth quarter 2006 and to provide financial guidance for 2007 at 2:00 p.m. PST on Thursday, March 1, 2007. Investors may listen to the webcast of the conference call live on Cell Genesys' website. Alternatively, investors may listen to a replay of the call by dialing 800-475-6701 from locations in the U.S. and 320-365-3844 from outside the U.S. The call-in replay will be available for at least 72 hours following the call. Please refer to reservation number 863676.
Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.
Contact: Ina Cu Investor Relations 650-266-3200 SELECTED CONSOLIDATED FINANCIAL INFORMATION CONSOLIDATED STATEMENTS OF OPERATIONS DATA (unaudited, in thousands except per share data) Three months ended Twelve months ended December 31, December 31, 2006 2005 2006 2005 Revenue $90 $85 $1,364 $4,584 Operating expenses: Research and development 24,633 21,030 96,346 92,405 General and administrative 4,435 4,986 18,123 16,342 Restructuring charges (25) 753 (82) 2,350 Total operating expenses 29,043 26,769 114,387 111,097 Loss from operations (28,953) (26,684) (113,023) (106,513) Other income (expense): Gain on sale of Abgenix, Inc. common stock -- 48,830 62,677 55,123 Interest and other income 2,088 748 7,495 3,058 Interest expense (2,607) (2,635) (10,465) (10,679) Income (loss) before income taxes (29,472) 20,259 (53,316) (59,011) Income tax provision (778) (1,203) (29,613) (5,928) Net income (loss) (30,250) 19,056 (82,929) (64,939) Dividend in kind to preferred stockholders -- -- -- (4) Net income (loss) attributed to common stockholders $(30,250) $19,056 $(82,929) $(64,943) Basic net income (loss) per common share $(0.54) $0.42 $(1.67) $(1.43) Diluted net income (loss) per common share $(0.54) $0.33 $(1.67) $(1.43) Weighted average shares of common stock outstanding -basic 55,522 45,547 49,728 45,434 Weighted average shares of common stock outstanding - diluted 55,522 61,616 49,728 45,434 CONSOLIDATED BALANCE SHEET DATA (in thousands) December 31, December 31, 2006 2005 (unaudited) Note 1 Cash, cash equivalents and short-term investments, including restricted cash $154,074 $129,139 Investment in Abgenix, Inc. common stock -- 63,824 Prepaid expenses and other current assets 3,481 2,563 Property and equipment, net 129,643 142,225 Noncurrent deferred tax assets -- 24,430 Unamortized debt issuance costs and other assets 3,969 4,794 Total assets $291,167 $366,975 Other current liabilities $15,904 $12,343 Accrued income taxes 35,410 32,612 Deferred income tax liabilities -- 24,430 Other liabilities 2,851 2,174 Non-current portion of capital lease obligation 48,475 49,919 Convertible senior notes 145,000 145,000 Stockholders' equity 43,527 100,497 Total liabilities and stockholders' equity $291,167 $366,975 Note 1. Derived from audited financial statements.
Cell Genesys, Inc.CONTACT: Ina Cu, Investor Relations of Cell Genesys, +1-650-266-3200
Web site: http://www.cellgenesys.com//
